Cleared Dual Track

Visby Medical Respiratory Health Test (K242526) - FDA 510(k) Clearance

Class II Microbiology device cleared through the Dual Track 510(k) pathway - typically does not require clinical trials.

K242526 · Visby Medical, Inc. · Microbiology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Feb 2025
Decision
177d
Days
Class 2
Risk

K242526 is an FDA 510(k) clearance for the Visby Medical Respiratory Health Test. Classified as Multi-target Respiratory Specimen Nucleic Acid Test Including Sars-cov-2 And Other Microbial Agents (product code QOF), Class II - Special Controls.

Submitted by Visby Medical, Inc. (San Jose, US). The FDA issued a Cleared decision on February 19, 2025 after a review of 177 days - an extended review cycle.

This device falls under the Microbiology FDA review panel, regulated under 21 CFR 866.3981 - the FDA microbiology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Microbiology review framework, consistent with the majority of Class II 510(k) submissions.

View all Visby Medical, Inc. devices

Submission Details

510(k) Number K242526 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received August 26, 2024
Decision Date February 19, 2025
Days to Decision 177 days
Submission Type Dual Track
Review Panel Microbiology (MI)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
75d slower than avg
Panel avg: 102d · This submission: 177d
Pathway characteristics

Device Classification

Product Code QOF Multi-target Respiratory Specimen Nucleic Acid Test Including Sars-cov-2 And Other Microbial Agents
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.3981
Definition A Device To Detect And Identify Nucleic Acid Targets In Respiratory Specimens From Microbial Agents That Cause The Sars-cov-2 Respiratory Infection And Other Microbial Agents When In A Multi-target Test Is An In Vitro Diagnostic Device Intended For The Detection And Identification Of Sars-cov-2 And Other Microbial Agents When In A Multi-target Test In Human Clinical Respiratory Specimens From Patients Suspected Of Respiratory Infection Who Are At Risk For Exposure Or Who May Have Been Exposed To These Agents. The Device Is Intended To Aid In The Diagnosis Of Respiratory Infection In Conjunction With Other Clinical, Epidemiologic, And Laboratory Data Or Other Risk Factors.
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Microbiology devices follow this clearance model.

Regulatory Peers - QOF Multi-target Respiratory Specimen Nucleic Acid Test Including Sars-cov-2 And Other Microbial Agents

All 30
Devices cleared under the same product code (QOF) and FDA review panel - the closest regulatory comparables to K242526.
Xpert Xpress CoV-2/Flu/RSV plus
K250996 · Cepheid · May 2025
cobas liat SARS-CoV-2 & Influenza A/B v2 nucleic acid test
K243400 · Roche Molecular Systems, Inc. · Apr 2025
cobas liat SARS-CoV-2, Influenza A/B & RSV nucleic acid test
K243406 · Roche Molecular Systems, Inc. · Apr 2025
Alinity m Resp-4-Plex
K241573 · Abbott Molecular, Inc. · Feb 2025
Xpert Xpress CoV-2/Flu/RSV plus
K242071 · Cepheid · Jan 2025
Applied Biosystems™ TaqPath™ COVID-19, Flu A, Flu B, RSV Select Panel
K241806 · Life Technologies Corporation · Jan 2025